U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H24N2S.ClH
Molecular Weight 348.933
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PROFENAMINE HYDROCHLORIDE

SMILES

Cl.CCN(CC)C(C)CN1C2=CC=CC=C2SC3=C1C=CC=C3

InChI

InChIKey=VXPCQISYVPFYRK-UHFFFAOYSA-N
InChI=1S/C19H24N2S.ClH/c1-4-20(5-2)15(3)14-21-16-10-6-8-12-18(16)22-19-13-9-7-11-17(19)21;/h6-13,15H,4-5,14H2,1-3H3;1H

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C19H24N2S
Molecular Weight 312.472
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21740955 | https://www.ncbi.nlm.nih.gov/pubmed/2904117

Ethopropazine is an anticholinergic drug. Ethopropazine is an inhibitor of butyrylcholinesterase and non-selective muscarinic acetylcholine receptor antagonist. Ethopropazine has been used for the treatment of parkinsonism and drug-induced extrapyramidal reactions. Also It used for the symptomatic treatment of hepatolenticular degeneration and congenital athetosis.

CNS Activity

Originator

Approval Year

1953
193
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 88.0 nM [Kd]
Antagonist
2778
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
PARSIDOL

Approved Use

Ethopropazine is indicated for the treatment of parkinsonism and drug-induced extrapyramidal reactions. Also used for the symptomatic treatment of hepatolenticular degeneration and congenital athetosis.
Primary
Approved
8429
PARSIDOL

Approved Use

Ethopropazine is indicated for the treatment of parkinsonism and drug-induced extrapyramidal reactions. Also used for the symptomatic treatment of hepatolenticular degeneration and congenital athetosis.
Primary
Approved
8429
PARSIDOL

Approved Use

Ethopropazine is indicated for the treatment of parkinsonism and drug-induced extrapyramidal reactions. Also used for the symptomatic treatment of hepatolenticular degeneration and congenital athetosis.
Primary
Approved
8429
PARSIDOL

Approved Use

Ethopropazine is indicated for the treatment of parkinsonism and drug-induced extrapyramidal reactions. Also used for the symptomatic treatment of hepatolenticular degeneration and congenital athetosis.
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
7%
OTHER
https://go.drugbank.com/drugs/DB00392
PROFENAMINE unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:313639
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:313639
eMolecules
1986772
https://www.emolecules.com/cgi-bin/more?vid=1986772
PubMed

PubMed

TitleDatePubMed
Abnormal involuntary movements induced by anticholinergic therapy.
1974
Amantadine in drug-induced extrapyramidal signs: a comparative study.
1975 Jun
Ethopropazine and benztropine in neuroleptic-induced parkinsonism.
1979 Mar
The relative selectivity of anticholinergic drugs for the M1 and M2 muscarinic receptor subtypes.
1986
Anti-nicotinic properties of anticholinergic antiparkinson drugs.
1998 Nov
Butyrylcholinesterase and cognitive function.
2001 Dec
Comparative effects of cationic triarylmethane, phenoxazine and phenothiazine dyes on horse serum butyrylcholinesterase.
2008 Oct 15
Recombinant expression and biochemical characterization of the catalytic domain of acetylcholinesterase-1 from the African malaria mosquito, Anopheles gambiae.
2009 Sep
Patents

Patents

JP2009240173A
3
JP2011528908A
3
JP5329434B2
3

Sample Use Guides

In Vivo Use Guide
ETHOPROPAZINE HYDROCHLORIDE TABLETS USP Usual adult and adolescent dose Parkinsonism and Drug-induced extrapyramidal reactions Oral, 50 mg one or two times a day, the dosage being increased as needed and tolerated. In severe cases, the dose may be increased gradually to a total of 500 to 600 mg a day.
Route of Administration: Oral
In Vitro Use Guide
The racemate and the enantiomers of ethopropazine were tested in vitro for their cellular toxicity using lung fibroblast cells. Each enantiomer was shown to be cytotoxic at concentrations greater than 10 uM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:36:49 UTC 2023
Edited
by admin
on Fri Dec 15 16:36:49 UTC 2023
Record UNII
O00T1I1VRN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ETHOPROPAZINE HYDROCHLORIDE
MI   ORANGE BOOK   VANDF  
Preferred Name English
PROFENAMINE HYDROCHLORIDE
JAN   MART.   WHO-DD  
Common Name English
Profenamine hydrochloride [WHO-DD]
Common Name English
ETHOPROPAZINE HCL
Common Name English
PROFENAMINE HYDROCHLORIDE [MART.]
Common Name English
NSC-169467
Code English
10H-PHENOTHIAZINE-10-ETHANAMINE, N,N-DIETHYL-.ALPHA.-METHYL-, HYDROCHLORIDE (1:1)
Systematic Name English
NSC-64074
Code English
PARSIDOL
Brand Name English
PROFENAMINE HYDROCHLORIDE [JAN]
Common Name English
ETHOPROPAZINE HYDROCHLORIDE [MI]
Common Name English
ETHOPROPAZINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
10-[2-(Diethylamino)propyl]phenothiazine monohydrochloride
Systematic Name English
ETHOPROPAZINE HYDROCHLORIDE [VANDF]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29578
Created by admin on Fri Dec 15 16:36:49 UTC 2023 , Edited by admin on Fri Dec 15 16:36:49 UTC 2023
Code System Code Type Description
CAS
1094-08-2
Created by admin on Fri Dec 15 16:36:49 UTC 2023 , Edited by admin on Fri Dec 15 16:36:49 UTC 2023
PRIMARY
SMS_ID
100000088525
Created by admin on Fri Dec 15 16:36:49 UTC 2023 , Edited by admin on Fri Dec 15 16:36:49 UTC 2023
PRIMARY
EVMPD
SUB04056MIG
Created by admin on Fri Dec 15 16:36:49 UTC 2023 , Edited by admin on Fri Dec 15 16:36:49 UTC 2023
PRIMARY
DRUG BANK
DB00392
Created by admin on Fri Dec 15 16:36:49 UTC 2023 , Edited by admin on Fri Dec 15 16:36:49 UTC 2023
PRIMARY
ECHA (EC/EINECS)
214-134-4
Created by admin on Fri Dec 15 16:36:49 UTC 2023 , Edited by admin on Fri Dec 15 16:36:49 UTC 2023
PRIMARY
EPA CompTox
DTXSID4045347
Created by admin on Fri Dec 15 16:36:49 UTC 2023 , Edited by admin on Fri Dec 15 16:36:49 UTC 2023
PRIMARY
NSC
169467
Created by admin on Fri Dec 15 16:36:49 UTC 2023 , Edited by admin on Fri Dec 15 16:36:49 UTC 2023
PRIMARY
NSC
64074
Created by admin on Fri Dec 15 16:36:49 UTC 2023 , Edited by admin on Fri Dec 15 16:36:49 UTC 2023
PRIMARY
NCI_THESAURUS
C65560
Created by admin on Fri Dec 15 16:36:49 UTC 2023 , Edited by admin on Fri Dec 15 16:36:49 UTC 2023
PRIMARY
ChEMBL
CHEMBL1206
Created by admin on Fri Dec 15 16:36:49 UTC 2023 , Edited by admin on Fri Dec 15 16:36:49 UTC 2023
PRIMARY
CHEBI
31568
Created by admin on Fri Dec 15 16:36:49 UTC 2023 , Edited by admin on Fri Dec 15 16:36:49 UTC 2023
PRIMARY
PUBCHEM
122824
Created by admin on Fri Dec 15 16:36:49 UTC 2023 , Edited by admin on Fri Dec 15 16:36:49 UTC 2023
PRIMARY
FDA UNII
O00T1I1VRN
Created by admin on Fri Dec 15 16:36:49 UTC 2023 , Edited by admin on Fri Dec 15 16:36:49 UTC 2023
PRIMARY
MERCK INDEX
m5070
Created by admin on Fri Dec 15 16:36:49 UTC 2023 , Edited by admin on Fri Dec 15 16:36:49 UTC 2023
PRIMARY Merck Index
RXCUI
6541
Created by admin on Fri Dec 15 16:36:49 UTC 2023 , Edited by admin on Fri Dec 15 16:36:49 UTC 2023
PRIMARY RxNorm
Related Record Type Details
Structure of PROFENAMINE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of PROFENAMINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966